Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism

Journal of Pharmacological Sciences

Volumn 102, Issue 1, 2006, Pages 37-46

  Iwata, Kazumi ^a   Matsuno, Kuniharu ^a   Nishinaka, Toru ^a   Persson, Christina ^b   Yabe Nishimura, Chihiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Aldose reductase; Heart; Ischemia reperfusion injury; Polyol pathway; Sorbitol dehydrogenase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CREATINE KINASE; EPALRESTAT; FIDARESTAT; POLYOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; GENE OVEREXPRESSION; GLYCOLYSIS; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFORMANCE; MOUSE; NONHUMAN; REPERFUSION INJURY; TISSUE LEVEL; TRANSGENIC MOUSE; TREATMENT OUTCOME; WILD TYPE;

EID: 33748954996     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060218     Document Type: Article

References (32)

1. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev. 1998;50:21-33.
2. Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, Knight DR, et al. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2000;279:H1447-H1452.
3. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol. 1998;275:H195-H203.
4. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997;46:292-300.
5. Hwang YC, Bakr S, Ellery CA, Oates PJ, Ramasamy R. Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 2003;17:2331-2333.
6. Shinmura K, Bolli R, Liu SQ, Tang XL, Kodani E, Xuan YT, et al. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res. 2002;91:240-246.
7. Lucas DT, Szweda LI. Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci U S A. 1998;95:510-514.
8. Eaton P, Li JM, Hearse DJ, Shattock MJ. Formation of 4-hydroxy-2-nonenal- modified proteins in ischemic rat heart. Am J Physiol. 1999;276:H935-H943.
9. Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, Hunsaker LA, et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta. 1995;1249:117-126.
10. Chu-Moyer MY, Ballinger WE, Beebe DA, Berger R, Coutcher JB, Day WW, et al. Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidines. J Med Chem. 2002;45:511-528.
11. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia. 1995;38:255-261.
12. Yagihashi S, Yamagishi S, Wada R, Baba M, Hohman TC, Yabe-Nishimura C, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain. 2001;124:2448-2458.
13. Yagihashi S, Yamagishi S, Wada R, Sugimoto K, Baba M, Wong HG, et al. Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes. 1996;45:56-59.
14. Seo HG, Nishinaka T, Yabe-Nishimura C. Nitric oxide upregulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling. Mol Pharmacol. 2000;57:709-717.
15. Guerrant G, Moss C. Determination of monosacchrides as aldononitrile, O-methyoxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem. 1984;56:633-638.
16. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357-363.
17. Nishinaka T, Yabe-Nishimura C. EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic Biol Med. 2001;31:205-216.
18. Srivastava S, Dixit BL, Ramana KV, Chandra A, Chandra D, Zacarias A, et al. Structural and kinetic modifications of aldose reductase by S-nitrosothiols. Biochem J. 2001;358:111-118.
19. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med. 1995;1:804-809.
20. Komarov AM, Kramer JH, Mak IT, Weglicki WB. EPR detection of endogenous nitric oxide in postischemic heart using lipid and aqueous-soluble dithiocarbamate-iron complexes. Mol Cell Biochem. 1997;175:91-97.
21. 2+ transport. Circ Res. 1995;77:88-97.
22. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J. 2005;19:795-797.
23. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 2004;18:1192-1199.
24. Jain M, Cui L, Brenner DA, Wang B, Handy DE, Leopold JA, et al. Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. 2004;109:898-903.
25. Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, et al. Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther. 1984;229: 226-230.
26. Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, et al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5- (trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J Med Chem. 1991;34:108-122.
27. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-257.
28. Lopaschuk GD, Spafford M. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res. 1989;65:378-387.
29. Nicholl TA, Lopaschuk GD, McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol. 1991;261:H1053-H1059.
30. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000;279:E1104-E1113.
31. + exchange during ischaemia and reperfusion of normal and diabetic rat hearts. Cardiovasc Res. 1990;24:873-878.
32. Paulson DJ, Kopp SJ, Peace DG, Tow JP. Improved postischemic recovery of cardiac pump function in exercised trained diabetic rats. J Appl Physiol. 1988;65:187-193.